MetaCap

Pliant Therapeutics (PLRX) vs Veru (VERU)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Veru (VERU) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 12.6% versus a loss of 61.6%. Over five years, PLRX leads with a -95.9% price change compared with -97.5% for VERU. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $33.1 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PLRX-61.61%VERU-12.61%
+98%+14%-69%
Nov 21, 20251 yearNov 20, 2026
PLRX-96.03%VERU-97.52%
+156%+23%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PLRX versus VERU key metrics
MetricPLRXVERU
Share price$0.5951$1.94
Market cap$36.89M$33.08M
1-day change-4.02%-8.06%
YTD return-51.22%-9.35%
1-year return-61.61%-12.61%
5-year return-95.89%-97.50%
EPS (TTM)$-1.46$-0.61
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-149.34M$-22.73M
52-week high$1.67$7.33
52-week low$0.5719$1.93
Distance from 52-week high-64.37%-73.53%
Analyst consensusnonestrong_buy
Avg. price target upside+236.08%+1223.20%
Average volume408.93K193.35K
Shares outstanding61.99M17.05M
Employees4920
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VERU has outperformed PLRX by 49.0 percentage points over the past year.

About Pliant Therapeutics

PLRX stock →

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

About Veru

VERU stock →

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees

PLRX vs VERU FAQ

Which is bigger, Pliant Therapeutics or Veru?

Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $33.08M for Veru (VERU).

Which stock has performed better over the past year, PLRX or VERU?

VERU returned -12.61% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.

Are Pliant Therapeutics and Veru in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons